Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in:

Open Access 01-12-2024 | Alzheimer's Disease | Letter

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Authors: Nerea Gómez de San José, Steffen Halbgebauer, Petra Steinacker, Sarah Anderl-Straub, Samir Abu-Rumeileh, Lorenzo Barba, Patrick Oeckl, Giovanni Bellomo, Lorenzo Gaetani, Andrea Toja, Sára Mravinacová, Sofia Bergström, Anna Månberg, Alberto Grassini, Innocenzo Rainero, Peter Nilsson, Lucilla Parnetti, Markus Otto

Published in: Translational Neurodegeneration | Issue 1/2024

Login to get access

Excerpt

The diagnosis of Alzheimer’s disease (AD) relies on the clinical evaluation of patients, often complemented by the analysis of core cerebrospinal fluid (CSF) biomarkers (Aβ42/40, phosphorylated-Tau and total-tau) [1]. However, it is clear nowadays that alterations other than Aβ and tau deposition, e.g., blood–brain-barrier (BBB) impairment [2] and impaired protein clearance [3], may take place in early disease stages, before consistent neurodegeneration occurs. Therefore, additional CSF biomarkers are needed. …
Appendix
Available only for authorised users
Literature
1.
Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–63.CrossRefPubMed
2.
3.
Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid beta clearance in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(4):33.CrossRefPubMedPubMedCentral
4.
Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997;17(1):171–80.CrossRefPubMedPubMedCentral
5.
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4(147):147ra111.CrossRefPubMedPubMedCentral
6.
Bergstrom S, Remnestal J, Yousef J, Olofsson J, Markaki I, Carvalho S, et al. Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer’s disease. Ann Clin Transl Neurol. 2021;8(7):1456–70.CrossRefPubMedPubMedCentral
7.
Arighi A, Arcaro M, Fumagalli GG, Carandini T, Pietroboni AM, Sacchi L, et al. Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation. Alzheimers Res Ther. 2022;14(1):135.CrossRefPubMedPubMedCentral
8.
Zeppenfeld DM, Simon M, Haswell JD, D’Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74(1):91–9.CrossRefPubMed
9.
Simren J, Weninger H, Brum WS, Khalil S, Benedet AL, Blennow K, et al. Differences between blood and cerebrospinal fluid glial fibrillary acidic protein levels: the effect of sample stability. Alzheimers Dement. 2022;18(10):1988–92.CrossRefPubMed
Metadata
Title
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease
Authors
Nerea Gómez de San José
Steffen Halbgebauer
Petra Steinacker
Sarah Anderl-Straub
Samir Abu-Rumeileh
Lorenzo Barba
Patrick Oeckl
Giovanni Bellomo
Lorenzo Gaetani
Andrea Toja
Sára Mravinacová
Sofia Bergström
Anna Månberg
Alberto Grassini
Innocenzo Rainero
Peter Nilsson
Lucilla Parnetti
Markus Otto
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2024
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-024-00451-8

Other articles of this Issue 1/2024

The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease

Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics

The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay

  • Open Access
  • Letter

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside